



OxySure (OXYS) Provides Corporate Update

FRISCO, TX -- (Marketwired – October 22, 2015) – OxySure Systems, Inc. (OTCQB: OXYS), (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other innovative medical solutions, announced today the release of a corporate update as presented by OxySure's CEO Julian Ross.

Mr. Ross began the update by stating, "We are excited to provide this update to our shareholders, employees, suppliers and customers to report on our progress during the past several months and in 2015 so far. We have been working diligently on numerous initiatives, including product diversification, manufacturing and quality upgrades, expanding our stellar Advisory Board, evaluating strategic acquisitions, and the process of uplisting of our Company to a national market such as NASDAQ."

Product Diversification

- ***The Quickclot® Bleeding Control Solution.*** The Company has expanded its portfolio of lifesaving medical devices by adding the QuikClot® hemostatic line of bleeding control devices to its current emergency medical and resuscitation product offerings. Quickclot® is designed for mass casualty events - acts of terrorism, natural disasters, active shooter situations or intentional acts of violence. These situations all require certain preparedness and response. Using QuikClot products in these situations can save lives by controlling bleeding. Uncontrolled bleeding is a major cause of preventable deaths. With QuikClot® hemostatic devices, medical personnel can stop bleeding faster, more effectively and without excessive costs.

The Hartford Consensus: Inspired by the Sandy Hook shooting incident the Hartford Consensus is a collaborative group of trauma surgeons, federal law enforcement, and emergency responders, and driven by the American College of Surgeons (ACS), the Federal Bureau of Investigation (FBI), Major Cities Chiefs Association and Prehospital Trauma Life Support program. It provides a model that is designed to improve the survivability of victims and implement life-saving methods among emergency personnel handling active shooter and intentional mass casualty events. An important part of this initiative requires all law enforcement officers to get medical training and equipment to control bleeding.

Recently, active shooter or mass casualty incidents such as the ones at Columbine High School (Littleton, Colo.), Sandy Hook Elementary (Newtown, Conn.), and the Century Movie Theater (Aurora, Colo.) have created a heightened awareness for solutions such as Quickclot.® "Controlling hemorrhage has to be a core law enforcement tactic," said

Alexander Eastman, MD, MPH, FACS, chief of trauma at UT Southwestern/Parkland Memorial Hospital, and Dallas Police Department lieutenant.

Added Julian Ross: “Immediately upon adoption, we have seen significant interest from various customer categories, including law enforcement, school districts, and even casinos. Our Quickclot customer base already includes customers such as Clark County School District Police Department, Gwinnett County Sheriff’s Department, City of Joseph DPS, and Dakota Sioux Casino Hotel, just to name a few, and we expect to accelerate the deployment of the solution to existing and additional customer categories.”

- More information about the Quickclot® bleeding control products can be found here: <http://www.oxysure.com/aed/index.php/quikclot-bleeding-control>
More information about the implementation of Bleeding Control under the Hartford Consensus can be found here: <http://bulletin.facs.org/2015/07/the-hartford-consensus-iii-implementation-of-bleeding-control/>
Facts about mass casualty incidents (MCI) can be found here: <http://www.oxysure.com/images/Know-the-Facts.jpg>
An OxySure brochure can be found here: <http://www.oxysure.com/hemorrhage%20control%20system.pdf>
- ***The Cardiac Science Powerheart® G5 AED.*** In August 2015 the Company rolled out the new Cardiac Science Powerheart® G5 automated external defibrillator to its sales team. The G5 is the most advanced Cardiac Science AED to date, and first-time rescuers will benefit from the Powerheart G5’s RescueCoach™ user-paced instruction, intuitive pad design, and automatic shock delivery to reduce the likelihood of human error.

“We have seen strong interest for the new Cardiac Science G5 unit,” said Clark Hood, Vice President of Resuscitation Sales for OxySure. “Customers across various segments have been buying it from us at a rapid pace, including the Dallas Mavericks, International Paper, Allstate Insurance, the YMCA, the Los Angeles Unified School District, the University of Texas at Dallas and numerous others.”

Manufacturing and Quality Improvements

“We have worked diligently and with a strong urgency to effect improvements to our manufacturing and quality system,” said Ross. “Working with our employees, vendors, contract manufacturers and the FDA we have spent thousands of hours working to effect improvements to our manufacturing and quality system. We are immensely proud of the thousands of lives our products have already saved and as we prepare to grow to the next level we believe this investment in time and resources will be well rewarded, especially as we prepare to address the needs of the millions of at risk patients in the asthma, immunology and allergy areas with the innovative OxySure Model 615 device.”

Strategic Advisory Board

The Company has recently announced stellar additions to its Strategic Advisory Board as the Company continues to forward-structure its Advisory Board to strengthen its collective expertise in healthcare marketing, sales and business development.

- ***Dr. Joseph M. Chalil, MD, MBA, FACHE.*** Dr. Chalil is a Physician and Executive at Boehringer Ingelheim, the world's largest privately held pharmaceutical company. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees, and 2014 net sales of \$13.3 billion euros. Dr. Chalil is an expert in US Healthcare policy and a strong advocate for patient centered care, and has also served as an advisor to various national political campaigns on healthcare issues. Dr. Chalil holds three US Patents, and his research includes Clinical Trial Management in Cystic Fibrosis, Multiple Myeloma, and publications in American Journal of Respiratory and Critical Care Medicine.
- ***Christopher Kaplan, M.Sc.*** Prior his current position as President of Cajetan, LLC Mr. Kaplan spent two years with Boehringer Ingelheim as Senior Vice President and Chief Marketing Officer. That followed 12 years at Novartis in both the US and Europe. Mr. Kaplan began at Novartis as Global Head of the Cardiovascular and Metabolic Business Franchise in Basel Switzerland, then moved to Head the Nordic Region Cluster and General Manager in Stockholm Sweden, and then became Head of Northern and Central Europe and Region Europe Marketing & Sales back in Basel. He returned to the US as President, Cardiovascular & Metabolic Operating Unit, in E. Hanover New Jersey, and then served as President and General Manager of the East Operating Unit, also in E. Hanover. Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company.

The current list of Strategic Advisory Board members is located here:

<http://oxysure.com/aed/index.php/strategic-advisory-board>

Evaluating Strategic Mergers/Acquisitions

“We continue to evaluate various strategic merger or acquisition opportunities in the first response (both pre-responder and responder markets) and general medical emergency and preparedness markets,” said Ross. “Some discussions are further along than others, and we look forward to updating our stockholders about any significant developments in this regard.”

Uplisting to Nasdaq

In addition to various financial, market and other qualitative and quantitative criteria, there are numerous corporate governance criteria to be met by companies seeking to uplist to a national exchange such as NASDAQ.

Mr. Ross stated: "We are pleased to finally have submitted our application package to NASDAQ. This caps several months of work, together with our partners Donohoe Advisory Associates to prepare and put in place the building blocks and meet the various sets of criteria required for uplisting. Our goal of uplisting to the NASDAQ stock exchange is expected to enhance our Company's visibility to the investment community, and to increasing the trading liquidity of our common stock. It will also further qualify the Company's common stock to be traded by institutional investors including mutual funds, pension funds and other institutional investment firms."

Other Developments and Looking ahead

"While 2015 is fast coming to a close we have several goals we are pursuing before year end. One of those goals is to advance the preparation for our approach to the "at risk" markets. We reiterate that are developing a clear, focused plan for addressing the millions of at risk patients in the asthma, immunology and allergy areas with our OxySure Model 615 product. We look forward to updating our stockholders, customers and partners as our plans progress.

I would like to take this opportunity to acknowledge and thank our team, our investors and our partners for their dedicated efforts and support thus far in 2015. We are very well positioned to build upon the positive momentum we generated in 2015 so far and carry that into 2016. We are blessed to have the passionate support of thousands of families, nurses, caregivers, coaches, and many other OxySure users and survivors. We remain committed to our mission to continue to save lives and help our customers with our high quality, innovative, and safe medical products," Mr. Ross concluded.

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYs) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. *In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products.* www.OxySure.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends",

"plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

Investor Contacts:

Renmark Financial Communications, Inc.

Bettina Filippone: bfilippone@renmarkfinancial.com

Richard Dupuy: rdupuy@renmarkfinancial.com

Tel.: (416) 644-2020 or (514) 939-3989

www.renmarkfinancial.com/

Redchip Companies, Inc.

Jon Cunningham: jon@redchip.com

800-733-2447, ext. 107

www.redchip.com/